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Abstract
Background: In the past decades, the prevalence of candidemia has increased significantly and
drug resistance has also become a pressing problem.  Overexpression of CDR1, an efflux pump, has
been proposed as a major mechanism contributing to the drug resistance in Candida albicans. It has
been demonstrated that biological fluids such as human serum can have profound effects on
antifungal pharmacodynamics. The aim of this study is to understand the effects of serum in drug
susceptibility via monitoring the activity of CDR1 promoter of C. albicans.
Results: The wild-type C. albicans cells (SC5314) but not the cdr1/cdr1 mutant cells became more
susceptible to the antifungal drug when the medium contained serum. To understand the regulation
of CDR1 in the presence of serum, we have constructed CDR1 promoter-Renilla luciferase (CDR1p-
RLUC) reporter to monitor the activity of the CDR1 promoter in C. albicans. As expected, the
expression of CDR1p-RLUC was induced by miconazole. Surprisingly, it was repressed by serum.
Consistently, the level of CDR1 mRNA was also reduced in the presence of serum but not N-acetyl-
D-glucosamine, a known inducer for germ tube formation.
Conclusion: Our finding that the expression of CDR1 is repressed by serum raises the question
as to how does CDR1 contribute to the drug resistance in C. albicans causing candidemia. This also
suggests that it is important to re-assess the prediction of in vivo therapeutic outcome of candidemia
based on the results of standard in vitro antifungal susceptibility testing, conducted in the absence
of serum.
Background
In the past decades, the prevalence of candidemia has
increased significantly. Among them, Candida albicans is
the most frequently isolated fungal pathogen in humans
and has caused morbidity in seriously debilitated and
immunocompromised hosts. Coinciding with the
increased usage of antifungal drugs, the incidences of drug
resistance have also increased [1,2].
Overexpression of CDR1, an ATP binding cassette (ABC)
transporter, has been shown to be the major mechanism
for the drug resistance of clinical isolates [3]. Mutations
on CDR1 in C. albicans have resulted in an increased sus-
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ceptibility to azole drugs [4], which is consistent with the
observation that overexpression of CDR1 contributes to
the drug resistance of clinical isolates of C. albicans [5].
Interestingly, the expression of CDR1 is increased approx-
imately 4-fold in Catup1/Catup1 mutant cells, which are
predominately in the hyphal form [6]. This data suggests
that CaTup1 acts as a negative regulator of CDR1.
Recently, two transcription factors, CaNDT80  and
CaTAC1, have been identified as positive regulators of
CDR1 in C. albicans [7,8].
Previous works have demonstrated that biological fluids
such as human serum can have profound effects on anti-
fungal pharmacodynamics [9]. During an infection, the C.
albicans cells exist in the host body and are surrounded by
blood and other body fluid, where they encounter the
antifungal drugs. In this study, we have found that the
wild-type SC5314 cells but not the cdr1/cdr1 mutant cells
became more susceptible to fluconazole, a commonly
used antifungal drug, when the medium contained serum.
To investigate the regulation of CDR1 in the presence of
serum, we have constructed a CDR1  promoter-Renilla
luciferase gene (CDR1p-RLUC) reporter to monitor the
activity of CDR1 promoter in C. albicans under different
conditions. In conclusion, serum increases the drug sus-
ceptibility by repressing the expression of CDR1.
Results and discussion
To determine if serum has any effect on the drug suscepti-
bility of C. albicans, we have determined the growth of
cells in the presence of different concentrations of fluco-
nazole and in the absence or presence of 10% fetal bovine
serum. The wild-type cells but not the cdr1/cdr1 mutant
cells became more susceptible to fluconazole when the
medium contained serum (Fig. 1). The growth of the wild-
type cells was less inhibited by 0.125 mg/l fluconazole in
serum-free medium than that in serum-containing one
(vertical dotted line). The minimum inhibitory concentra-
tion (MIC) of fluconazole of the cdr1/cdr1 mutant cells
(0.0625 mg/l) was lower than that of the wild-type cells
(0.25 mg/l). This is consistent with the previous reports
that mutations on CDR1 have resulted in an increased
drug susceptibility [4,7]. The MIC of fluconazole of the
wild-type cells was 2-fold lower in serum-containing
medium than that in serum-free one (0.125 mg/l vs. 0.25
mg/l).
It is generally accepted that overexpression of CDR1 is the
major mechanism for the drug resistance of clinical iso-
lates [3,5,10]. Our finding that the wild-type cells but not
the cdr1/cdr1 mutants became more susceptible to fluco-
nazole in serum-containing medium led us to further
investigate the effects of serum on CDR1 expression. First
of all, we have constructed a CDR1p-RLUC reporter (Fig.
2). The construct was integrated into the CDR1 locus and
its activities under different conditions in different strains
were determined. The results are summarized in Figure 3.
The C. albicans cells containing CDR1p-RLUC were har-
vested after being grown in Synthetic Dextrose (SD) liquid
medium in the absence or presence of 100 mg/l of mico-
nazole at 35°C for one hour. The expression of CDR1p-
RLUC was induced approximately 2-fold by miconazole
(Fig. 3, comparing bar 1 to bar 2). This datum is consistent
with the previously report that the expression of CDR1 is
induced by miconazole [11] and also suggests that the
activity of CDR1p-RLUC can refer the expression of CDR1
under our experimental setup.
To determine the effect of serum on the expression of
CDR1, we have measured the activities of CDR1p-RLUC in
C. albicans cells that were grown in SD liquid medium in
the absence or presence of 10% fetal bovine serum at
35°C for one hour. Surprisingly, the serum repressed the
expression of CDR1p-RLUC. In the presence of the serum,
the expression of CDR1p-RLUC was reduced to 50% of
that in the absence of the serum (Fig. 3, comparing bar 1
to bar 3). To determine if human serum also has the same
effect, we have also cultured the cells in the presence of
10% human serum from two healthy volunteers. Interest-
ingly, like the fetal bovine serum, the human sera also
reduced the expression of CDR1p-RLUC (Fig. 3, compar-
ing bar 1 to bars 4 and 5).
This datum suggests that if the activity of CDR1p-RLUC
echoes the expression of endogenous CDR1, the level of
CDR1 mRNA would be reduced when C. albicans cells
Fluconazole susceptibility testing Figure 1
Fluconazole susceptibility testing. The inhibition on 
growth by fluconazole was determined by microdilution 
method. The wild-type strain (SC5314, squares) and the 
cdr1/cdr1 mutant cells (DSY448, triangles) were grown in the 
absence (solid symbols) or presence of 10% fetal bovine 
serum (open symbols). The optical density (OD) of each well 
was read at 600 nm after incubated at 35°C for 48 hours. 
The horizontal dotted line represents 50% inhibition and the 
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were grown in the presence of serum. To investigate this
hypothesis, we have measured the level of CDR1 mRNAs
in different strains by real-time PCR. In the presence of
10% fetal bovine serum, the level of CDR1 mRNA in the
wild-type cells was reduced to approximately 50% of that
in the absence of the serum (Fig. 4, comparing bar 1 to bar
2), which re-assured the result of the activity assay with
CDR1p-RLUC. These results conclude that serum represses
the expression of CDR1. Since serum is a key stimulant for
hyphal formation of C. albicans, we would like to deter-
mine whether its effect on CDR1 expression is due to a fac-
tor solely present in serum or common in other hypha-
inducing media also. Consequently, we have determined
if 5 mM N-acetyl-D-glucosamine (Glu-NAc), a known
inducer for germ tube formation of C. albicans would alter
the expression of CDR1 [12,13]. Unlike serum, Glu-NAc
did not have effect on the expression of CDR1 (Fig. 4,
comparing bar 1 and bar 3). This result suggests that the
expression of CDR1  is not repressed by every hypha-
inducing medium. This is consistent with the previously
reported that the expression of CDR1  is increased in
Catup1/Catup1 mutant cells, which are predominately in
hyphal form [6].
Recently, CaNdt80 has been identified as a positive regu-
lator of CDR1 in C. albicans [7]. To investigate if serum
represses the expression of CDR1 via CaNdt80, we have
also determined the level of CDR1 in Candt80/Candt80
mutant cells. The expression of CDR1 was reduced 50%
by the null mutation of CaNDT80 (Fig. 4, comparing bar
1 to bar 4), which is consistent with our previous finding
that CaNdt80 regulates CDR1 positively [7]. If regulating
the expression of CDR1 by serum is independent of the
activity of CaNdt80, the level of CDR1  mRNA in the
Candt80/Candt80  mutant cells would be significantly
reduced in the presence of serum. Otherwise, it will not (if
there is any). Our data showed that although 10% fetal
bovine serum further reduced the expression of CDR1 in
the  Candt80/Candt80  mutant cells, the effect was mild
(Fig. 4, comparing bar 4 to bar 5).
Construction of CDR1 promoter-Renilla luciferase Figure 2
Construction of CDR1 promoter-Renilla luciferase. The PCR products containing the promoter and the translation ini-
tiation site of CDR1 (open box) were introduced in-frame with the sequence encoding luciferase (RLUC, hatched box) into the 
plasmid pGEM with the wild-type URA3 gene as the selective marker. The LOB 85 plasmid was linearized with EcoRV, trans-
formed, and integrated into the chromosome at the promoter of CDR1 (solid box) in C. albicans.
Digested with EcoRV and
transformed into C. albicans
EcoRV EcoRV
CDR1 p URA3 Amp RLUC CDR1 p CDR1









CDR1 pBMC Molecular Biology 2006, 7:22 http://www.biomedcentral.com/1471-2199/7/22
Page 4 of 6
(page number not for citation purposes)
Conclusion
We have found that the wild-type cells became more sus-
ceptible to fluconazole when the medium contained
serum. Furthermore, the expression of CDR1 is repressed
significantly by serum according to the activity of the
reporter and CDR1 mRNA level. The level of CDR1 mRNA
was only mildly reduced by serum in the Candt80/
Candt80 mutant cells suggesting the major, if not the sole,
regulatory ability of serum may be through the activity of
CaNdt80. However, we still can not rule out the possibil-
ity that serum may also act through Tac1 and/or other uni-
dentified regulators. It will be interesting to investigate the
coordination between CaNdt80 and Tac1 in regulating
the expression of CDR1 in the presence of serum.
The standard antifungal susceptibility testing [14], which
is conducted in the absence of serum, is unreliable in pre-
dicting the clinical outcome of therapies, especially for
systemic infections. Our finding may explain the existence
and persistence of such a discrepancy between the suscep-
tibilities of in vivo and in vitro environments.
Methods
Strains and media
Strains of C. albicans used in this studyare as following:
SC5314, the wild-type control strain; DSY448, ura3Δ::
λimm434/ura3Δ:: λimm434; DSY448, ura3Δ:: λ imm434/
ura3Δ::  λimm434 cdr1::hisG/cdr1::hisG-URA3-hisG, a gift
from Dr. D. Sanglard [4]; YLO133, ura3Δ::  λimm434/
ura3Δ::  λimm434 his1::hisG/his1::hisG arg4::hisG/
arg4::hisG Candt80::GFP-Arg4/Candt80::URA3-dpl20
ENO1/eno1::ENO1-tetR-SCHAP4-3xHA-HIS1; and
YLO137,  ura3Δ::  λimm434/ura3Δ::  λimm434 his1::hisG/
his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/
Candt80:: URA3-dpl200:: CaNDT80::HIS1 [7]. Yeast Pep-
tone Dextrose (YPD) contained 1% yeast extract, 2% pep-
tone, and 2% dextrose and Synthetic Dextrose (SD)
contained 0.67% yeast nitrogen base without amino acid
and 2% dextrose. All agar plates were prepared with addi-
tion of 2% agar in media.
Antifungal drug susceptibility
The minimum inhibitory concentration (MIC) to flucona-
zole of each strain was determined by in vitro antifungal
susceptibility testing using microdilution method accord-
ing to published guidelines by the Clinical and Laboratory
Standards Institute (CLSI, formerly NCCLS) [14]. The
antifungal agent fluconazole (Pfizer, Inc.) was freshly pre-
pared as a stock at the concentration of 16 g/l in DMSO.
For working concentration, (16~0.0312 μg/ml), it was
processed by stepwise twofold dilutions in SD medium. A
drug-free culture and a sterile control were included in
each microtitre plate. The optical density (OD) in each
well of the microtitre plate was read with a microplate
reader (Molecular Devices, SPECTRA MAX plus) at 600
nm after incubated at 35°C for 48 hours. The drug inhib-
itory curve was presented by the OD of each well with dif-
ferent concentrations of fluconazole relative to the OD of
the drug-free control. The MIC was defined as the lowest
concentration which reduced the culture broth turbidity
by 50%.
The level of CDR1 mRNA Figure 4
The level of CDR1 mRNA. Total RNA was isolated from 
cells in the absence of serum (bars 1, 4, 7), in the presence of 
10% fetal bovine serum (bars 2, 5, 8), or in the presence of 5 
mM Glu-NAc (bars 3, 6, 9). The level of RNA isolated from 
the wild-type cells in the absence of serum was defined as 
one and the relative level of mRNA isolated from different 
strains was normalized accordingly. Bars 1–3, CaNDT80/
CaNDT80 (SC5314); bars 4–6, Candt80/Candt80 (YLO133), 





































The activity assay of CDR1 promoter-Renilla luciferase gene Figure 3
The activity assay of CDR1 promoter-Renilla luci-
ferase gene. The activity of luciferase from control cells 
(bar 1) was defined as one. The activity of luciferase from 
cells in the presence of miconazole or sera was normalized 
accordingly. Bar 1, with neither serum nor miconazole; bar 2, 
with 100 μg/ml of miconazole; bar 3, with 10% fetal bovine 
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Construction of CDR1 promoter-Renilla luciferase
A 1.2 kilo-base-pair (kb) DNA fragment containing the
RLUC gene modified for C. albicans with the WH11 tran-
scription termination sequence at the 3' end of the RLUC
open reading frame was isolated from pCRW3 [11] after
digested with EcoRV and NcoI. The purified DNA fragment
was blunt-ended with klenow and then ligated to the
pGEM-URA [15] at the NaeI site to construct the plasmid
LOB60. Another 1.2 kb DNA fragment containing the pro-
moter and the translation initiation site of CDR1 was gen-
erated by using oligonucleotides HJL340, 5'-
d(GATCATCGATACTCAATAAG) and HJL 341, 5'-
d(CGCAAGCCCGGGTAATTTTTTTC). The plasmid
LOB60 was then used to construct plasmid LOB85 by
introducing the PCR product at restriction sites of ClaI and
XmaI (Fig. 2). The resulted LOB85 was then linearized
with EcoRV at the 455 base-pair (bp) upstream of the
translation initiation site of CDR1 and used for transfor-
mation to integrate into the chromosome at the promoter
of  CDR1  of CAI4 to produce the Ura3+ transformant,
YLO185,  ura3Δ::  λimm434/ura3Δ::  λimm434 CDR1p-
RLUC-URA3 (Fig. 2).
Activity assay of CDR1 promoter-Renilla luciferase gene 
(CDR1p-RLUC)
Overnight pre-cultured C. albicans cells containing
CDR1p-RLUC  were diluted in 10 ml of the SD liquid
medium to a final concentration about 4 × 106 cells per
ml. Prior to the addition of serum or miconazole, the
dilutents were incubated at 30°C for 4 hours. The cells
were harvested after treated with 10% serum (either the
fetal bovine serum provided by JRH Biosciences, Australia
or the human serum from two coauthors) or 100 μg/ml of
miconazole (Sigma M-3512) at 35°C for one hour. The
control cells were grown in SD medium in the absence of
serum and miconazole at 35°C for one hour. The cells
were resuspended in lysis buffer for luciferase assay using
the Dual-Glo Luciferase Assay System (E2940, Promega,
Madison, USA). The activity of luciferase was determined
according to the protocol provided by the manufacturer.
The activity of luciferase in the control cells without treat-
ment was defined as one and the relative activity of luci-
ferase in cells with other treatments was normalized
accordingly.
Quantitative analysis of the mRNA level by Real-Time PCR
The C. albicans cells were harvested at an OD600 between
0.7 and 0.9 after being grown in 20 ml of the SD liquid
medium in the absence or presence of 10% fetal bovine
serum (JRH Biosciences, Australia) or 5 mM Glu-NAc
(Sigma, A8625) at 37°C for one hour. A real-time PCR
was performed in a Rotor-Gene™ 3000 instrument (Cor-
bett Research, Australia) with a TITANIUM™ Taq PCR kit
(BD Clontech 639210) and SYBR®Green I Nucleic Acid
Stain (Cambrex 50513) to determine the level of mRNA.
The sample was automatically setup by CAS-1200™ (Cor-
bett Research, Australia). The real-time PCR was per-
formed according to the instructions from the
manufacturer. The expression of TEF3 in each strain was
used as the control. The relative quantitation was based
on two standard curves for comparisons and the results
were given as a ratio [16]. The level of CDR1 mRNA iso-
lated from the wild-type cells in the absence of serum was
defined as one. The relative level of mRNA isolated from
different strains was normalized accordingly.
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